680,000 patients in the USA alone suffer from End Stage Renal Disease and millions more around the world.
ESRD treatment costs Medicare $34 billion per year.
Nearly 100,000 Americans are on the wait list for a kidney transplant. Average wait time is 3-7 years.
US Kidney Research Corporation (formerly Curion Research Corporation), is a Delaware
C-Corp founded in June, 2015. For over 4 years, US Kidney Research Corporation has been involved in R&D of the world’s first waterless renal replacement technology. Unlike standard dialysis, our new technology does not require purified water, dialysate concentrate solutions, or a dialyzer.
Initially, our technology will be used to develop a wearable artificial kidney. Ultimately, the same technology can be used in a standalone waterless renal therapy machine and implantable devices.
First in the world to create synthetic urine using a new blood purifying technology that involves filtration and ion transport processes similar to the native kidney. Animal studies performed at Noble Life Sciences using our latest prototype - Maryland
Award winner of KidneyX Redesign Dialysis Phase 1 contest sponsored in partnership by US Dept. of Health and Human Services and the American Society of Nephrology.
Invited as Guest speaker by International Federation for Artificial Organs (IFAO) to present at the American Society for Implantable Artificial Organs (ASAIO) Chicago conference in June 2020.
Science article recently published in Nature, the premier science journal in the world. Entitled:
Simulating nephron ion transport function using activated wafer electrodeionization
US Patent Filed.
PCT international patents filed in 44 countries.
This revolutionary technology for purifying the blood of patients with end stage kidney disease has the potential to completely replace current dialysis procedures in an industry that has not changed its methodology in decades. In collaboration with advisers and research scientists from two major universities,
US Kidney Research Corporation has made significant progress in achieving its goals. It is our intention to bring this new technology to clinical practice and help all those suffering from end stage renal disease.
US Kidney Research Corporation has developed a unique technology that represents a fundamental paradigm shift in renal replacement therapy.